Related Experiment Video
Updated: Aug 22, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Notified Body guidance on clinical evaluation
1Donawa and Associates Ltd, Rome, Italy. donawa@srd.it
Abstract:
Under the European Directives, manufacturers must demonstrate that medical devices are safe, perform as intended, and that any associated risks are acceptable. Where appropriate, these characteristics should be based on clinical data. This article discusses guidance documents developed to assist Notified Bodies in reviewing the manufacturer's evaluation of clinical data.
Related Concept Videos
Clinical Trials: Overview
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Toxicity Testing in Animals
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...